Phase Ib Study of Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Patients With Metastatic Breast Cancer
Phase of Trial: Phase I
Latest Information Update: 28 Aug 2019
Price : $35 *
At a glance
- Drugs Rebastinib (Primary) ; Eribulin; Paclitaxel
- Indications Adenocarcinoma; Advanced breast cancer
- Focus Adverse reactions
- 22 Aug 2019 Planned primary completion date changed from 1 Jul 2019 to 1 Jul 2020.
- 31 Aug 2018 Biomarkers information updated
- 22 Mar 2018 Planned End Date changed from 1 Jul 2019 to 1 Jul 2020.